Novartis AGNVSNYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank86
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P86
Within normal range
vs 2Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
20255.89%
20240.39%
20232.66%
2022-4.94%
2021-9.65%
2020-1.20%
20194.75%
201810.04%
2017-12.17%
2016-0.39%